{"name":"ORA, Inc.","slug":"ora-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"Systane (r) Ultra","genericName":"Systane (r) Ultra","slug":"systane-r-ultra","indication":"Dry eye syndrome / dry eye disease","status":"marketed"},{"name":"PL9643 Ophthalmic Solution","genericName":"PL9643 Ophthalmic Solution","slug":"pl9643-ophthalmic-solution","indication":"Dry eye disease","status":"phase_3"},{"name":"Placebo Ophthalmic Solution","genericName":"Placebo Ophthalmic Solution","slug":"placebo-ophthalmic-solution","indication":"Treatment of dry eye syndrome","status":"phase_3"},{"name":"Rohto (r) Hydra","genericName":"Rohto (r) Hydra","slug":"rohto-r-hydra","indication":"Dry eye syndrome / Dry eye disease","status":"marketed"},{"name":"Tears Naturale II Ophthalmic Solution","genericName":"Tears Naturale II Ophthalmic Solution","slug":"tears-naturale-ii-ophthalmic-solution","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Patanol","genericName":"Patanol","slug":"patanol","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Lastacaft ®","genericName":"Lastacaft ®","slug":"lastacaft","indication":"Allergic conjunctivitis (itching associated with allergic conjunctivitis)","status":"marketed"},{"name":"Olopatadine Nasal Spray","genericName":"Olopatadine Nasal Spray","slug":"olopatadine-nasal-spray","indication":"Allergic rhinitis (nasal symptoms)","status":"marketed"},{"name":"Saline Nasal Spray","genericName":"Saline Nasal Spray","slug":"saline-nasal-spray","indication":"Nasal congestion relief","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ST-100 (vezocolmitide)","genericName":"ST-100 (vezocolmitide)","slug":"st-100-vezocolmitide","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Prednisolone Acetate 0.12%","genericName":"Prednisolone Acetate 0.12%","slug":"prednisolone-acetate-0-12","indication":"Inflammation and pain following ocular surgery","status":"marketed"}]}],"pipeline":[{"name":"Patanol","genericName":"Patanol","slug":"patanol","phase":"marketed","mechanism":"Histamine H1 receptor, Histamine H1 receptor","indications":["Allergic conjunctivitis","Allergic rhinitis","Seasonal allergic rhinitis"],"catalyst":""},{"name":"ST-100 (vezocolmitide)","genericName":"ST-100 (vezocolmitide)","slug":"st-100-vezocolmitide","phase":"phase_3","mechanism":"ST-100 (vezocolmitide) is a small molecule that modulates the Wnt/β-catenin signaling pathway.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Systane (r) Ultra","genericName":"Systane (r) Ultra","slug":"systane-r-ultra","phase":"marketed","mechanism":"Systane Ultra is a lubricating eye drop that provides sustained moisture and relief to the ocular surface by forming a protective film.","indications":["Dry eye syndrome / dry eye disease"],"catalyst":""},{"name":"Lastacaft ®","genericName":"Lastacaft ®","slug":"lastacaft","phase":"marketed","mechanism":"Lastacaft is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.","indications":["Allergic conjunctivitis (itching associated with allergic conjunctivitis)"],"catalyst":""},{"name":"Olopatadine Nasal Spray","genericName":"Olopatadine Nasal Spray","slug":"olopatadine-nasal-spray","phase":"marketed","mechanism":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the nasal mucosa.","indications":["Allergic rhinitis (nasal symptoms)"],"catalyst":""},{"name":"PL9643 Ophthalmic Solution","genericName":"PL9643 Ophthalmic Solution","slug":"pl9643-ophthalmic-solution","phase":"phase_3","mechanism":"PL9643 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production in ocular tissues.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"Placebo Ophthalmic Solution","genericName":"Placebo Ophthalmic Solution","slug":"placebo-ophthalmic-solution","phase":"phase_3","mechanism":"This is a placebo ophthalmic solution, meaning it has no active therapeutic effect.","indications":["Treatment of dry eye syndrome"],"catalyst":""},{"name":"Prednisolone Acetate 0.12%","genericName":"Prednisolone Acetate 0.12%","slug":"prednisolone-acetate-0-12","phase":"marketed","mechanism":"Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammation and pain following ocular surgery","Allergic conjunctivitis","Anterior uveitis","Corneal injury from chemical, radiation, or thermal burns"],"catalyst":""},{"name":"Rohto (r) Hydra","genericName":"Rohto (r) Hydra","slug":"rohto-r-hydra","phase":"marketed","mechanism":"Rohto Hydra is an ophthalmic lubricant that provides moisture and relief to dry eyes by forming a protective hydrating layer on the ocular surface.","indications":["Dry eye syndrome / Dry eye disease"],"catalyst":""},{"name":"Saline Nasal Spray","genericName":"Saline Nasal Spray","slug":"saline-nasal-spray","phase":"marketed","mechanism":"Saline nasal spray delivers a sterile salt-water solution to the nasal passages to cleanse, moisturize, and relieve nasal congestion.","indications":["Nasal congestion relief","Nasal irrigation and cleansing","Dry nasal passages","Post-nasal drip management"],"catalyst":""},{"name":"Tears Naturale II Ophthalmic Solution","genericName":"Tears Naturale II Ophthalmic Solution","slug":"tears-naturale-ii-ophthalmic-solution","phase":"marketed","mechanism":"Tears Naturale II is an artificial tear solution that lubricates and protects the ocular surface by mimicking natural tear composition.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Temporary relief of ocular irritation and discomfort"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPZjVCMGxyd0U5dkdEV3hZVDM5cFRpU1VDbFpNUHNvbHU5dDhWYnV4cGFvelFMRkkyZGttRWZmVDlsN2FiWjl6ZXFHTTUwR25CQnhBelVTRTZ2VDBRam5aaHczMG9WSFZVOThKS1RlNWVGTmZzWEpMVllTbDg5QUVjMzdYUDVZX05WZmcwbzd0bzJNd0ZMamZaMnlkaXpaN0hl?oc=5","date":"2026-03-26","type":"earnings","source":"Yahoo Finance","summary":"Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance","headline":"Innate Pharma Q4 Earnings Call Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNUnNYY1V3YjJjSjQzTEZ0SmFnc0tmai1pX2Q4N05MYl9YU1FEWHZ5QnIxdDhScmo4OUU3WWtRNDVJZ1ZCbmlSTGNGV3dENVRidGlhZ3lPTHdfQ0R4SGoyOFFIdGgxbC1RLWYxTE5nZ0dIajV6cFA2WDRPdzJVT2JOb3g4dV9WeG5Sck9aNWZNZ3lnR04tRWN3VG0yS3ZNallCMjBGYnNYWjlPNG11Qk14WQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Stock Titan","summary":"The gum disease antibiotic dentists have used for 25 years, explained - Stock Titan","headline":"The gum disease antibiotic dentists have used for 25 years, explained","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQakdTY3c2b1Z5M3ZZSU5yaFBqMUNJaVBDZkdvYVQ1RllzWld2OFE3Qi13TDF4TFVQbkxNbldrV3NucDBUQUtVampNMzh2VkZlbFZFdmh2WVg1UTZ4UFJoR0JfQThHeklaZURRT0ZUUzA4Mnkxb2UwMFpuem5Ua3ZNSGc2cmdIWVE3Nk04ekk3bHk3aERsVzFrLXRTUUVKWEV3aVlvMHV5V0p3UTEzUlhNdzJNR0UzZWFnYWlZMm5R?oc=5","date":"2025-11-19","type":"pipeline","source":"24-7 Press Release Newswire","summary":"Marquis Who's Who Honors Jeanne Hecht for Expertise in Life Sciences - 24-7 Press Release Newswire","headline":"Marquis Who's Who Honors Jeanne Hecht for Expertise in Life Sciences - 24-7 Press Release Newswire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQMjJxa1NTNzFJMExOZHc2emp6eVZjVWVlMFhJTUs0UzZqSWl1UzFycG5BLWREaTJBckRWbTMxTFdHMW5Fd3B1bVNzcVo4cDNhYWRxWlRtUGdZTUdhQVhZVjRXdXQ4dnVoRExvOHBxR2Zub0NoY2EtaW5nMEdyVXRhNURtbVZrNF9xTUVZaW13VTFZTjdTMmt3NVJxQUNZbzJTUnJjQ3U1X09yd1RaeHBrYWViMG1xZGNGU215YThNOUJGc24wZlNzRjRoREdoLXVLdlh5RFdud1J6UmxzZEpGOE90d2IwWnB0ay1fSWZ3dGM?oc=5","date":"2025-09-19","type":"pipeline","source":"Ropes & Gray LLP","summary":"Janet Coscino Named to Chicago Lawyer’s 2025 40 Under Forty Illinois Attorneys to Watch - Ropes & Gray LLP","headline":"Janet Coscino Named to Chicago Lawyer’s 2025 40 Under Forty Illinois Attorneys to Watch - Ropes & Gray LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNM0ZPUzhMUEt0ZHNVYTU5RV91OWs4QUhIV2tYWFM5Yl9tdExESkVnSjVtY29Kbld5WU5HRE93MUhmejR3VDZWS05vMHhlcVdoZFQxM29ZSURZWENYTU84cmJWRUhPOTJNZkVSazI2eVNPTktkS3dUd1RFTFJRU1VfS3ByWm9lQ2lLQ2U1RmhzVng5NWxuV191S3NQUzZMYXZsSUVEb2dGUXM1MVJxaG5BTnFaQWVFVzBpLVJZYi1Uam1RekVZUDhRdVpGdmNrLVI3RVdJRERn?oc=5","date":"2025-07-16","type":"pipeline","source":"businesswire.com","summary":"Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors - businesswire.com","headline":"Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNbVhmb1NBWDVTX0hyZ1ZyQ3hKQzZ5Q0RQcTlzRDVkcVFsd2Nyd3JsQUNlZi13c3M0UEZSeHI1dlpSQ1haZEVrN3lmX3BLSEIwWXFFQ0xNTUI2RzBkRk4taWFBMjJEbGlhWGFOSi1Zb2N1dTNNdFdpUUw4aHRIdVM3MHpIS1NBQkRyelJIakhjSTlfYWZ6TThkd3h2NDJDbjJWZmV4M0NKV1RYczRTUFQxY2Z3QkpzZW0xaTRoS1E3aXFtUVdEVmc?oc=5","date":"2025-07-09","type":"deal","source":"Eyes On Eyecare","summary":"LENZ and Théa partner on Canadian commercialization of presbyopia eye drop - Eyes On Eyecare","headline":"LENZ and Théa partner on Canadian commercialization of presbyopia eye drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOcWFIaUx0MUJsNnhDbHZKWVFrSjM2Tk94NWlyUTFsNkdhaFpVMmhwQnRpTnlWUEs0bEl0aWRkX3A0XzJ4cjBmWFRiRGdnb29wbE1CNHVfU3JYYnJ2eFlPa21FWGdjMTh1XzRaa01icjdfUDZtSUNmS3lCR3c4emJXZnVMRThwaGpN?oc=5","date":"2024-08-22","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Acquisitions – July 2024 - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Acquisitions – July 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdlAyWjhTRldQXzhnTGctVDZYbU55c0pJOHRZWlZvUmdQR3AxdGltNkJVTDB5Xy1hVWZyOVpxdlRCcXRvd050SWZKN3BhS3lnMmEyb21RRTVKTU91OUtwY0pDOHdNalAyaGtSNUNORnFJcXFWNnNMd01wb1VyaE4xSExhaThmaENTaHNwVEI0SEk0RkJLcTVyaDVrQ3hVb3h4RGJjeDVzb21OZVo1aDNDbEhMdnJ4Zmtn?oc=5","date":"2024-03-11","type":"trial","source":"Eyes On Eyecare","summary":"Positive topline data released for Telios Pharma's DED treatment - Eyes On Eyecare","headline":"Positive topline data released for Telios Pharma's DED treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQcUFZcUJLZG9HRUxHSjRmcWQ5c3pRWWsySjhLVVVNQWkxaTVuVmQ0U0FuRFpad1BIZnhibTZUZnBveDlsbk0xUzZMMm9PbWZHdTlUdzB6TTFJdVFWdEVURVRIOHBvU1p0dnZpV1J3UnZVX1l3SGVqWGVidW9uNXhMNTJ1akY5ZERGd3dnYkh2MEJiYk0xd0V3Njdpb25KNThxbU5F?oc=5","date":"2023-11-06","type":"pipeline","source":"Fierce Pharma","summary":"CRO Ora launches new AI project to highlight the experience of blindness - Fierce Pharma","headline":"CRO Ora launches new AI project to highlight the experience of blindness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQbzJXS2VYdzUxY0dWa2ZPOEZ1ZmQxN3ZpSG5GMGVGTHJHSzNGa3RzdHIwcEtTX1F1czBjMVlIMDVNWVktZ18yRzE4SWU0bjJYV05FVzNYaENhVXBwLXJJeVQ4V2pTclZmU3huZ1FfUzA0MXVibFhTUnZUZDNiUXRXR2JJcVBoZ3c4ZUJCRzh5eTBZZkp1UnZ5TGRBZUNSZHc4ajJNemdYQ1FKWmduTmd0TnpPZ0p3Zw?oc=5","date":"2023-06-28","type":"pipeline","source":"businesswire.com","summary":"Ora, Inc. Appoints Nate Speicher as Chief Financial Officer - businesswire.com","headline":"Ora, Inc. Appoints Nate Speicher as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOYlM1b2lNMG1BRnhnNkV0am5mMDFkZ2pPSGZNZ1dYNGROODNyWnktUV9oZ000eDNreDltWE1NQ3ZjbC00cV9BVUhEYmstMElYb3BJdkhTSTFZaGlVVFE5WnR0QUlJZ1BOdVItUDYtZmQwLVVpbkRDVWVSMGZfWWxRbThQcFU2dndoSzdmdjVmUjRYNm9SeGZDaFRLLWpCUjRMMDluZXhyMnZHRFo3R2lXTDdSYw?oc=5","date":"2023-04-06","type":"pipeline","source":"businesswire.com","summary":"Ora, Inc. Appoints Paul Colvin as Chief Operating Officer - businesswire.com","headline":"Ora, Inc. Appoints Paul Colvin as Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBTdk01ZEVnR3A1WG4yMThmbFlRWDlhUC1DckR6S1BsV0paSlZlV1FXSnBDUTczdVBxMmJUUElwcEUwTEVJbDZEeTEydnN5YVRWOXIyMk1XYjJiY29kNER2UjN1Y3JDMUc4SW9vZ01QYVN2d2RO?oc=5","date":"2020-08-10","type":"pipeline","source":"Fierce Pharma","summary":"Fierce Pharma Sits Down with Ora - Fierce Pharma","headline":"Fierce Pharma Sits Down with Ora","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":8,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}